Zyban: A Clinically Proven Aid for Smoking Cessation
Zyban
| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.00 | $40.00 (0%) | 🛒 Add to cart |
| 20 | $3.00 | $80.00 $60.00 (25%) | 🛒 Add to cart |
| 30 | $2.33 | $120.00 $70.00 (42%) | 🛒 Add to cart |
| 60 | $1.33 | $240.00 $80.00 (67%) | 🛒 Add to cart |
| 90 | $1.00 | $360.00 $90.00 (75%) | 🛒 Add to cart |
| 120 | $0.83 | $480.00 $100.00 (79%) | 🛒 Add to cart |
| 180 | $0.75 | $720.00 $135.00 (81%) | 🛒 Add to cart |
| 270 | $0.67 | $1080.00 $180.00 (83%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $1440.00 $210.00 (85%) | 🛒 Add to cart |
Similar products
Zyban (bupropion hydrochloride) is a prescription medication specifically developed to support adults in their journey to quit smoking. Unlike nicotine replacement therapies, Zyban works by affecting neurotransmitters in the brain associated with nicotine addiction and withdrawal. It is designed to reduce the urge to smoke and alleviate withdrawal symptoms, providing a non-nicotine pharmacological approach to smoking cessation. Clinical studies have demonstrated its efficacy when used as part of a comprehensive cessation program that includes behavioral support and counseling.
Features
- Active ingredient: Bupropion hydrochloride
- Available in extended-release tablets (150 mg)
- Non-nicotine based smoking cessation aid
- Requires a prescription from a healthcare provider
- Manufactured under strict pharmaceutical quality standards
Benefits
- Reduces the severity of nicotine cravings and withdrawal symptoms
- Increases the likelihood of long-term smoking abstinence compared to placebo
- Does not contain nicotine, avoiding replacement dependency
- Can be used as part of a structured behavioral support program
- May help prevent weight gain often associated with quitting smoking
- Supported by robust clinical trial data demonstrating efficacy and safety
Common use
Zyban is indicated as an aid to smoking cessation treatment in adults. It is intended for use in conjunction with behavioral modifications, counseling, and support programs designed to address the psychological and habitual aspects of smoking. Treatment should be initiated while the patient is still smoking, with a target quit date set for the end of the first week of treatment. The full course of therapy typically lasts 7 to 12 weeks, though duration may be adjusted based on individual response and healthcare provider assessment.
Dosage and direction
The recommended dosage for Zyban is 150 mg once daily for the first 3 days, followed by an increase to 150 mg twice daily. Doses should be taken at least 8 hours apart to minimize the risk of insomnia. Tablets should be swallowed whole and not crushed, divided, or chewed. It is advisable to avoid taking the medication too close to bedtime due to potential activation effects. Treatment should be continued for 7 to 12 weeks; if abstinence has not been achieved by week 7, continued use is unlikely to be beneficial. Dosage adjustments are not typically required for elderly patients or those with hepatic or renal impairment, though caution is advised and medical supervision is essential.
Precautions
Patients should be monitored for neuropsychiatric symptoms including changes in behavior, hostility, agitation, depressed mood, and suicidal thoughts or actions. Zyban lowers the seizure threshold; caution is advised in patients with conditions that predispose to seizures (e.g., head trauma, CNS tumors, concomitant medications that lower seizure threshold). Use with caution in patients with hepatic or renal impairment. Blood pressure should be monitored, as elevations have been reported. Zyban contains the same active ingredient as certain antidepressants; concomitant use with other bupropion-containing products is contraindicated.
Contraindications
Zyban is contraindicated in patients with a seizure disorder or history of seizures. It must not be used in patients with a current or prior diagnosis of bulimia or anorexia nervosa due to the higher incidence of seizures in such patients. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated; at least 14 days should elapse between discontinuation of an MAOI and initiation of Zyban. Hypersensitivity to bupropion or any component of the formulation is also a contraindication.
Possible side effects
Common adverse reactions include dry mouth, insomnia, headache, nausea, dizziness, and pharyngitis. Less frequently, patients may experience tremor, rash, sweating, tinnitus, agitation, anxiety, constipation, and taste disturbance. Serious side effects may include seizures, allergic reactions, hypertension, psychiatric symptoms (e.g., suicidal ideation, hostility), and angle-closure glaucoma. Patients should be advised to report any unusual or severe symptoms promptly to their healthcare provider.
Drug interaction
Zyban is metabolized primarily by CYP2B6 and inhibits CYP2D6. Concomitant use with drugs that lower the seizure threshold (e.g., antipsychotics, antidepressants, theophylline, systemic corticosteroids) may increase seizure risk. Caution is advised with drugs metabolized by CYP2D6 (e.g., certain antidepressants, antipsychotics, beta-blockers, type 1C antiarrhythmics) as bupropion may increase their plasma levels. Concurrent use with levodopa or amantadine may increase the risk of adverse effects. Alcohol should be avoided or minimized due to increased risk of neuropsychiatric events.
Missed dose
If a dose is missed, it should be skipped and the regular dosing schedule resumed. Do not double the dose to make up for a missed one, as this may increase the risk of adverse effects including seizures. Patients should be advised to maintain a consistent dosing routine and to contact their healthcare provider if multiple doses are missed or if they are unsure how to proceed.
Overdose
Overdose may lead to seizures, hallucinations, loss of consciousness, sinus tachycardia, and ECG changes such as QRS prolongation. Fatal outcomes have been reported, particularly with mixed overdoses involving multiple drugs. Management of overdose requires symptomatic and supportive care; activated charcoal may be considered if presented early. Seizures should be treated with benzodiazepines; additional anticonvulsants may be required. ECG and vital signs should be monitored continuously in a healthcare setting.
Storage
Store at room temperature (20°C to 25°C/68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the bottle tightly closed and protect from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Dispose of unused medication properly via a drug take-back program or according to local regulations.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Individual patient responses may vary, and only a healthcare professional can assess suitability based on medical history, concurrent conditions, and other medications.
Reviews
Clinical trials and post-marketing surveillance have demonstrated Zyban’s efficacy in supporting smoking cessation, with abstinence rates approximately double that of placebo at end of treatment and at 1-year follow-up. Many patients report reduced cravings and easier management of withdrawal symptoms. However, individual experiences vary, and success often depends on adherence to medication and participation in behavioral support programs. Some users note side effects such as insomnia or dry mouth, though these often diminish over time. Healthcare providers generally regard Zyban as a valuable option within a comprehensive smoking cessation strategy.